Hormone replacement therapy and cardiovascular disease revisited

Area of Science:

• Cardiovascular Health
• Endocrinology
• Women's Health

Background:

• Controversy exists regarding the cardiovascular benefits and risks of hormone replacement therapy (HRT).
• Estrogen demonstrates biological benefits for cardiovascular health, supported by epidemiological data.
• Previous findings from the Women's Health Initiative (WHI) trial suggested HRT increased coronary events.

Purpose of the Study:

• To re-evaluate the cardiovascular benefits and risks of hormone replacement therapy (HRT) in postmenopausal women.
• To clarify the impact of HRT on coronary heart disease (CHD) prevention.
• To assess the safety and efficacy of HRT in light of updated Women's Health Initiative (WHI) data.

Main Methods:

• Analysis of comprehensive data from the Women's Health Initiative (WHI) randomized, placebo-controlled clinical trial.
• Examination of cardiovascular events, stroke, venous thromboembolism, and breast cancer incidence in HRT users versus placebo.
• Subgroup analysis based on age at initiation of HRT.

Main Results:

• Updated WHI data show no significant increase in coronary heart disease (CHD) with HRT.
• A trend towards reduced CHD was observed in women initiating HRT before age 60.
• Subsequent findings did not confirm a clear increase in breast cancer risk associated with HRT.

Conclusions:

• Preliminary WHI findings did not accurately represent the true benefits and risks of HRT.
• HRT should be considered a potential preventive treatment for coronary heart disease (CHD) in postmenopausal women.
• HRT may be particularly beneficial for primary prevention of CHD when initiated at a younger age.